Header

UZH-Logo

Maintenance Infos

Pegfilgrastim primary prophylaxis vs. current practice neutropenia management in elderly breast cancer patients receiving chemotherapy


Aapro, M; Schwenkglenks, M; Lyman, G H; Lopez Pousa, A; Lawrinson, S; Skacel, T; Bacon, P; von Minckwitz, G (2010). Pegfilgrastim primary prophylaxis vs. current practice neutropenia management in elderly breast cancer patients receiving chemotherapy. Critical Reviews in Oncology / Hematology, 74(3):203-210.

Abstract

We investigated the incidences of febrile neutropenia (FN) and related complications in elderly (>/=65 years) breast cancer patients receiving chemotherapy supported by pegfilgrastim primary prophylaxis (PP; n=150) or current practice (CP) neutropenia management (n=104) in a subanalysis of NeuCuP (Neulasta((R)) vs. current practice neutropenia management). Studies involving regimens with moderately high to high (>/=15%) FN risk were identified by literature review, and individual patient data were integrated for analysis. FN incidence was 6% (95% CI: 2, 10%) in the PP group and 24% (95% CI: 16, 32%) in the CP group. In cycle 1, incidences were 3 and 15%, respectively. FN-related hospitalisation incidence was 5% (PP group) and 15% (CP group), while dose reductions (>/=15%) occurred in 15 and 29% of patients. Pegfilgrastim provided effective PP in elderly patients, a population who may be vulnerable to chemotherapy-related FN and for whom current practice may not provide adequate protection.

Abstract

We investigated the incidences of febrile neutropenia (FN) and related complications in elderly (>/=65 years) breast cancer patients receiving chemotherapy supported by pegfilgrastim primary prophylaxis (PP; n=150) or current practice (CP) neutropenia management (n=104) in a subanalysis of NeuCuP (Neulasta((R)) vs. current practice neutropenia management). Studies involving regimens with moderately high to high (>/=15%) FN risk were identified by literature review, and individual patient data were integrated for analysis. FN incidence was 6% (95% CI: 2, 10%) in the PP group and 24% (95% CI: 16, 32%) in the CP group. In cycle 1, incidences were 3 and 15%, respectively. FN-related hospitalisation incidence was 5% (PP group) and 15% (CP group), while dose reductions (>/=15%) occurred in 15 and 29% of patients. Pegfilgrastim provided effective PP in elderly patients, a population who may be vulnerable to chemotherapy-related FN and for whom current practice may not provide adequate protection.

Statistics

Citations

14 citations in Web of Science®
19 citations in Scopus®
Google Scholar™

Altmetrics

Downloads

368 downloads since deposited on 15 Jan 2010
31 downloads since 12 months
Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > Epidemiology, Biostatistics and Prevention Institute (EBPI)
Dewey Decimal Classification:610 Medicine & health
Language:English
Date:June 2010
Deposited On:15 Jan 2010 12:07
Last Modified:06 Dec 2017 23:20
Publisher:Elsevier
ISSN:1040-8428
Publisher DOI:https://doi.org/10.1016/j.critrevonc.2009.06.004
PubMed ID:19748281

Download

Download PDF  'Pegfilgrastim primary prophylaxis vs. current practice neutropenia management in elderly breast cancer patients receiving chemotherapy'.
Preview
Content: Accepted Version
Filetype: PDF
Size: 1MB
View at publisher